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Aims The effect of first-line antianginal agents, b-blockers, and calcium antagonists on clinical outcomes in stable coron-
ary artery disease (CAD) remains uncertain.
...................................................................................................................................................................................................
Methods
and results
We analysed the use of b-blockers or calcium antagonists (baseline and annually) and outcomes in 22 006 stable
CAD patients (enrolled 2009–2010) followed annually to 5 years, in the CLARIFY registry (45 countries). Primary
outcome was all-cause death. Secondary outcomes were cardiovascular death and the composite of cardiovascular
death/non-fatal myocardial infarction (MI). After multivariable adjustment, baseline b-blocker use was not associated
with lower all-cause death [1345 (7.8%) in users vs. 407 (8.4%) in non-users; hazard ratio (HR) 0.94, 95% confidence
interval (CI) 0.84–1.06; P= 0.30]; cardiovascular death [861 (5.0%) vs. 262 (5.4%); HR 0.91, 95% CI 0.79–1.05;
P= 0.20]; or cardiovascular death/non-fatal MI [1272 (7.4%) vs. 340 (7.0%); HR 1.03, 95% CI 0.91–1.16; P= 0.66].
Sensitivity analyses according to b-blocker use over time and to prescribed dose produced similar results. Among
prior MI patients, for those enrolled in the year following MI, baseline b-blocker use was associated with lower all-
cause death [205 (7.0%) vs. 59 (10.3%); HR 0.68, 95% CI 0.50–0.91; P= 0.01]; cardiovascular death [132 (4.5%) vs.
49 (8.5%); HR 0.52, 95% CI 0.37–0.73; P= 0.0001]; and cardiovascular death/non-fatal MI [212 (7.2%) vs. 59 (10.3%);
HR 0.69, 95% CI 0.52–0.93; P= 0.01]. Calcium antagonists were not associated with any difference in mortality.
...................................................................................................................................................................................................
Conclusion In this contemporary cohort of stable CAD, b-blocker use was associated with lower 5-year mortality only in
patients enrolled in the year following MI. Use of calcium antagonists was not associated with superior mortality,
regardless of history of MI.
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..Introduction
b-blockers and calcium antagonists are recommended for treatment
of angina in patients with stable coronary disease (CAD).1,2 They are
widely used in stable CAD, including angina free patients3 even
though their role in improving outcomes remains uncertain. Large
observational series have shown association of b-blocker use with
improved outcomes in acute coronary syndromes.4–6
Randomized clinical trials (RCTs) established unequivocal benefits
of b-blockers in chronic heart failure with left ventricular (LV) systolic
dysfunction7 and in relatively old trials in acute myocardial infarction
(MI),8 but no trials assessed their benefit compared with placebo
in stable CAD.9,10 Thus, the question was investigated in observation-
al11–14 and post hoc trial analyses.15
Regarding calcium antagonists, there are no data supporting a
benefit on mortality and a few trials supporting a benefit on cardio-
vascular morbidity compared with placebo in stable CAD.16,17 Trials
comparing long-acting dihydropyridines18 or non-dihydropyri-
dines19–21 with b-blockers in stable CAD found no difference in clin-
ical outcomes.
In the absence of RCTs, we assessed the association between b-
blocker or calcium antagonist use and clinical outcomes, focusing on
mortality, in the prospective observational longitudinal registry of
patients with stable CAD (CLARIFY; ISRCTN43070564) acknowl-
edging that residual confounding factors from measured or unmeas-
ured variables can persist even after adjustment.
Methods
Design, setting and participants
The present study is a post hoc analysis of the CLARIFY registry. The regis-
try design has been previously described.3 Briefly, 32 703 stable CAD
outpatients were enrolled (November 2009–June 2010) in 45 countries
and followed annually up to 5 years.
Patients were eligible for enrolment if they fulfilled >_1 of the following
criteria (not mutually exclusive): documented MI >3 months ago; coron-
ary artery bypass grafting (CABG) or percutaneous coronary interven-
tion (PCI) >3 months ago; chest pain with proven myocardial ischaemia;
or previous coronary angiography showing >_1 coronary stenosis >50%.
Exclusion criteria were hospitalization for cardiovascular disease within
the previous 3 months; planned revascularization; and conditions interfer-
ing with life expectancy including severe heart failure. Medical care was at
the discretion of each physician. Each year 1% of the sites were randomly
selected for on-site audits of 100% of data reporting.
CLARIFY was conducted in accordance with the Declaration of
Helsinki and local ethical approval was obtained in each country. All
patients gave informed consent.
Study outcomes
The primary outcome was all-cause mortality. Secondary outcomes were
cardiovascular mortality and the composite of cardiovascular mortality/
non-fatal MI. Exploratory analyses examined non-cardiovascular mortal-
ity, MI (fatal/non-fatal), and stroke (fatal/non-fatal).
Cardiovascular mortality was defined as death following MI or stroke,
and other cardiovascular mortality (death ascribed to heart failure, car-
diac or vascular procedure/surgery, ruptured aneurysm, pulmonary em-
bolism). Unknown causes of death and death that could not be definitely
ascribed to non-cardiovascular mortality were classed as cardiovascular
for analyses. Outcomes were not adjudicated, but reported by
investigators.
Statistical analyses
b-blocker and calcium antagonist use was assessed at baseline and yearly.
Patients with a history of MI were categorized according to the delay
since prior MI at the time of enrolment in three subgroups: <_1 year, 1 to
<_3 years, and >3 years post-MI.
To account for the treatment status (b-blockers or calcium antago-
nists) of the patient prior to the event, sensitivity analyses were per-
formed using as covariates the last available record of the use of
b-blocker or calcium antagonist before an event. To assess the impact of
b-blocker daily doses, sensitivity analyses based on <_half dose, half to
<_full dose, or full target dose were performed. Full doses were defined
according to usual clinical therapeutic dose for each b-blocker. For the
five most frequently used b-blockers with an indication for post-MI sec-
ondary prevention, for LV systolic dysfunction, or for angina relief, full tar-
get daily doses were defined as 10 mg for bisoprolol,22 200 mg for
metoprolol,23 100 mg for atenolol,18 50 mg for carvedilol,24 and 10 mg for
nebivolol.25
Hazard ratios (HRs) associated with b-blocker use vs. non-use and cal-
cium antagonist use vs. non-use, and 95% confidence intervals (CIs) were
calculated from Cox proportional hazards models. Hazard ratios were
estimated after adjustment for cardiovascular risk factors, medical history
of cardiovascular disease, treatments, geographical areas, and pulmonary
comorbidities: systolic and diastolic blood pressure, LV ejection fraction,
history of revascularization by PCI/CABG, asthma or chronic obstructive
pulmonary disease (COPD), and the REACH cardiovascular event risk
score.26 The REACH score (detailed in Supplementary material online,
Table S1) was used to adjust for sex, age, current smoking, diabetes, body
mass index <20 kg/m2, number of vascular beds involved (cerebrovascu-
lar, peripheral, and coronary artery disease), history of recent MI
(<_1 year), heart failure or atrial fibrillation, statin or aspirin therapies, and
geographical zones. Multivariable analyses were performed in patients
who had a complete dataset for all the variables entered in the models,
constituting the study cohort. In order to address missing data, especially
regarding LV systolic function, a sensitivity analysis considered the same
model with LV ejection fraction as a categorical variable (including a miss-
ing category).
The sensitivity analysis pertaining to the relation between b-blocker
daily dose and outcomes, used an adjustment model based on the
REACH risk score.
Data were managed and analysed by the Robertson Centre for
Biostatistics (University of Glasgow, UK). All analyses were conducted
using R and the survival package.27
Results
A total of 32 378 participants were available for analysis. At the end
of 4 years 5111 (15.8%) and 5108 (15.8%) were censored respective-
ly in the b-blocker analysis and the calcium antagonist analysis (details
in Supplementary material online, Tables S2 and S3). Overall a com-
plete baseline dataset (with follow-up and no missing covariates) was
available for 22 006 (68.0%) in the b-blocker use analysis, and for
22 004 (68.0%) for the calcium antagonist analysis. The sensitivity ana-
lysis including patients in whom LV ejection fraction was missing
involved 31 987 patients (98.8% of the total study population).
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b-blocker analyses
At baseline, b-blockers were used in 17 135 (77.9%) patients. Among
4871 non-users, 1931 had a prior history of intolerance or contra-
indication to b-blockers, mainly due to asthma/COPD (n= 558),
bradycardia (n= 555), fatigue (n= 551), erectile dysfunction
(n= 270), and hypotension (n= 269). For patients in whom dose was
available, 45.1% received less than half of the target dose, 41.6% half
to less than full dose, and 13.3% the full target dose. The five most fre-
quently used b-blockers were bisoprolol (35.6%), metoprolol
(27.2%), carvedilol (12.6%), atenolol (12.3%), and nebivolol (6.5%).
....................................................................................................................................................................................................................
Table 1 Baseline characteristics among patients analysed in the multivariable adjusted model according to b-blocker
use (n522 006) or calcium antagonist use (n522 004)
Variables b-blockers
(n5 17 135)
No b-blockers
(n5 4871)
P-value Calcium
antagonists
(n5 5885)
No calcium
antagonists
(n5 16 119)
P-value
REACH cardiovascular event risk score 11.00 (9.00–13.00) 11.00 (9.00–13.00) 11.00 (9.00–13.00) 11.00 (9.00–13.00)
11.2 ± 3.1 11.1 ± 3.2 0.49 11.5 ± 3.1 11.0 ± 3.2
CV risk factors
Gender male 78.3% 78.0% 0.70 74.0% 79.8% <0.0001
Age (years) 63.3 ± 10.5 65.5 ± 10.7 <0.0001 65.7 ± 10.0 63.1 ± 10.7 <0.0001
Smoking
Current 12.3% 11.9% 10.2% 13.0%
Former 46.5% 46.8% 45.3% 47.0%
Never 41.2% 41.3% 0.74 44.6% 40.1% <0.0001
Family history of premature CAD 29.1% 28.3% 0.33 29.2% 28.8% 0.55
Treated hypertension 74.0% 66.1% <0.0001 87.4% 66.7% <0.0001
Diabetes 30.4% 26.6% <0.0001 35.8% 27.3% <0.0001
Dyslipidaemia 79.0% 78.0% 0.12 82.9% 77.3% <0.0001
Past medical history
Myocardial infarction 64.8% 52.5% <0.0001 52.5% 65.6% <0.0001
Percutaneous coronary intervention 58.9% 56.8% 0.01 55.6% 59.5% <0.0001
Peripheral arterial disease 10.3% 13.1% <0.0001 14.1% 9.8% <0.0001
Carotid disease 8.9% 9.0% 0.82 12.0% 7.8% <0.0001
Stroke 3.8% 4.4% 0.06 5.4% 3.4% <0.0001
Hospitalization for CHF 5.9% 4.6% 0.0006 5.1% 5.8% 0.07
Atrial fibrillation/flutter 7.8% 7.5% 0.53 8.3% 7.5% 0.04
Asthma/COPD 5.0% 5.8% <0.0001 10.0% 6.4% <0.0001
Clinical examination
Systolic blood pressure (mmHg) 131.0 ± 16.8 131.1 ± 15.8 0.61 135.3 ± 16.7 129.5 ± 16.2 <0.0001
Diastolic blood pressure (mmHg) 77.7 ± 10.0 77.2 ± 9.6 0.001 78.4 ± 10.2 77.3 ± 9.8 <0.0001
Resting heart rate (b.p.m.) 67.4 ± 10.3 69.7 ± 11.3 <0.0001 68.4 ± 10.6 67.7 ± 10.6 <0.0001
Current angina 25.0% 21.4% <0.0001 28.1% 22.8% <0.0001
Current heart failure symptoms 20.1% 13.0% <0.0001 18.9% 18.4% 0.43
LVEF measurements
Mean LVEF % 55.6 ± 11.1 58.0 ± 10.4 <0.0001 57.9 ± 10.1 55.5 ± 11.2 <0.0001
LVEF <_45% 18.7% 12.8% <0.0001 12.3% 19.3% <0.0001
Medications
Aspirin 89.1% 83.8% <0.0001 86.7% 88.3% 0.002
Thienopyridine 28.5% 29.5% 0.16 28.6% 28.7% 0.81
Dual antiplatelet therapy 28.9% 27.0% 0.009 26.8% 28.3% 0.03
Statins 85.6% 79.8% <0.0001 84.1% 84.4% 0.49
Angiotensin-converting enzyme inhibitors 57.2% 42.7% <0.0001 48.8% 55.9% <0.0001
Angiotensin II receptor blockers 25.5% 31.5% <0.0001 35.6% 23.6% <0.0001
b-blockers NA NA NA 69.6% 80.9% <0.0001
Calcium antagonists 23.9% 36.7% <0.0001 NA NA NA
Data are % for categorical data, and mean ± standard deviation or median (interquartile range) for continuous data depending on the distribution.
CAD, coronary artery disease; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; NA, not available.
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Three quarters of patients were male. Compared with non-users,
users were younger, had higher prevalence of cardiovascular risk fac-
tors, more frequent history of previous MI or hospitalization for
heart failure, and less frequent asthma/COPD. Users had lower rest-
ing heart rate, similar blood pressure, and higher prevalence of cur-
rent heart failure symptoms. Twenty-five percent of users had
current angina despite b-blocker therapy. They had lower LV systolic
function and received more frequently evidence-based preventive
treatments. Despite these differences in baseline characteristics, the
REACH cardiovascular risk score was similar between groups
(Table 1). Baseline characteristics of all enrolled patients with data
pertaining to b-blocker use gave similar results (Supplementary ma-
terial online, Table S4).
Overall, the rate of death was 1.80 per 100 patient years. Event
rates are detailed in Supplementary material online,Table S5. For the
primary and secondary outcomes, multivariable adjusted HRs
showed no association between b-blocker use at baseline and out-
comes. The HR for all-cause mortality was 0.94 (95% CI 0.84–1.06)
(Take home figure, Table 2). Hazard ratios for cardiovascular mortality
and the composite of cardiovascular mortality/non-fatal MI were 0.91
(95% CI 0.79–1.05) and 1.03 (95% CI 0.91–1.16), respectively.
Regarding exploratory analyses, there were no associations between
b-blockers and outcomes (Table 2).
Among patients with MI <_1 year prior to enrolment, b-blocker
use was associated with a lower risk of all-cause mortality [205
(7.0%) for users vs. 59 (10.3%) for non-users, HR 0.68, 95% CI 0.50–
0.91; P= 0.01], lower cardiovascular mortality [132 (4.5%) for users
vs. 49 (8.5%) for non-users, HR 0.52, 95% CI 0.37–0.73; P= 0.0001],
and lower cardiovascular mortality/non-fatal MI [212 (7.2%) for users
vs. 59 (10.3%) for non-users, HR 0.69, 95% CI 0.52–0.93; P= 0.01].
....................................................................................................................................................................................................................
Table 2 Multivariable adjusted associations according to b-blocker use and calcium antagonist use at baseline
5-Year outcomes b-blockers
(n5 17 135)
No b-blockers
(n5 4871)
HR (95% CI) P-value Calcium
antagonists
(n5 5885)
No calcium
antagonists
(n516 119)
HR (95% CI) P-value
Primary outcome
All-cause mortality 1345 (7.8%) 407 (8.4%) 0.94 (0.84–1.06) 0.30 493 (8.4%) 1259 (7.8%) 1.02 (0.91–1.13) 0.76
Secondary outcomes
Cardiovascular mortality 861 (5.0%) 262 (5.4%) 0.91 (0.79–1.05) 0.20 311 (5.3%) 812 (5.0%) 1.01 (0.88–1.16) 0.87
Cardiovascular
mortality/non-fatal MI
1272 (7.4%) 340 (7.0%) 1.03 (0.91–1.16) 0.66 457 (7.8%) 1155 (7.2%) 1.05 (0.94–1.17) 0.39
Exploratory analyses
Non-cardiovascular mortality 484 (2.8%) 145 (3.0%) 1.00 (0.83–1.21) 0.99 182 (3.1%) 447 (2.8%) 1.03 (0.86–1.22) 0.77
MI 587 (3.4%) 140 (2.9%) 1.14 (0.94–1.37) 0.18 214 (3.6%) 513 (3.2%) 1.12 (0.95–1.32) 0.17
Stroke 375 (2.2%) 92 (1.9%) 1.13 (0.89–1.42) 0.32 150 (2.5%) 317 (2.0%) 1.18 (0.96–1.43) 0.11
HRs, CIs, and P-values are derived from comparing b-blocker users/non-users and calcium antagonist users/non-users at baseline in a survival analysis using Cox proportional
hazards models with multivariable adjustment for the REACH cardiovascular event score,26 systolic/diastolic blood pressure, left ventricular ejection fraction, history of percu-
taneous coronary artery, coronary artery bypass graft, peripheral artery disease, and asthma/chronic obstructive pulmonary disease.
CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.
Figure 1 Cumulative hazard of all-cause mortality according to ß-blocker use at baseline, categorized by the time elapsed since the index myocar-
dial infarction prior to enrolment. P-values, hazard ratios, and confidence intervals are derived from comparing b-blocker users to non-users at base-
line in a survival analysis from Cox proportional hazards models with multivariable adjustment for the REACH cardiovascular event risk score,26
systolic/blood pressure, left ventricular ejection fraction, history of coronary revascularization, peripheral artery disease, and asthma/chronic
obstructive pulmonary disease. CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.
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..In patients with prior MI >1 year, there was no difference in out-
comes between groups (Figure 1, Take home figure, and Table 3).
In patients with no history of PCI, b-blocker use at baseline was
associated with lower cardiovascular death [427 (6.1%) for users vs.
155 (7.4%) for non-users and HR 0.81, 95% CI 0.67–0.98; P= 0.03]
(Supplementary material online, Table S6). There was no association
between b-blocker use and mortality after categorization by pres-
ence of angina (Supplementary material online, Table S7). Sensitivity
analyses according to the last assessment of b-blocker use prior to an
event showed consistent results with no difference in risk for all out-
comes except for an association with stroke (HR 1.39, 95% CI 1.10–
1.74; P= 0.005) (Supplementary material online, Table S8).
Sensitivity analyses pertaining to b-blocker doses showed consist-
ent results (Supplementary material online,Table S9).
When considering LV ejection fraction as a categorical variable
and including a missing category, analyses performed among 31 987
patients showed consistent results. b-blocker use (n= 24 119) com-
pared with non-use (n= 7868) was not associated with lower all-
cause death [1856 (7.7%) and 666 (8.5%), respectively with a HR
0.96, 95% CI 0.87–1.05; P= 0.33] or lower cardiovascular death
[1184 (4.9%) and 419 (5.3%), respectively with HR 0.95, 95% CI
0.85–1.07; P= 0.43] (Supplementary material online, Table S10).
Calcium antagonist analyses
At baseline, calcium antagonists were used in 5885 (26.7%) patients.
Among users, 4697 (79.8%) were receiving long-acting dihydropyri-
dines, 864 (14.7%) diltiazem and 286 (4.9%) verapamil.
Users included more females, were older, with higher prevalence
of cardiovascular risk factors, more frequent history of peripheral ar-
tery disease, carotid disease, stroke or asthma/COPD, and less fre-
quent history of prior MI or hospitalization for heart failure. Users
Take home figure Multivariable adjusted associations with all-cause mortality according to b-blocker use and calcium antagonist use at base-
line, overall and after categorization by time since myocardial infarction prior to enrolment. P-values, hazard ratios, and confidence intervals are
derived from comparing b-blocker users to non-users and calcium antagonist users to non-users at baseline in a survival analysis from Cox propor-
tional hazards models with multivariable adjustment for the REACH cardiovascular event risk score,26 systolic/blood pressure, left ventricular ejec-
tion fraction, history of coronary revascularization, peripheral artery disease, and asthma/chronic obstructive pulmonary disease. CI, confidence
interval; HR, hazard ratio; MI, myocardial infarction.
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had higher resting heart rate and blood pressure. They had higher
prevalence of current anginal symptoms, despite calcium antagonist
therapy, and higher LV ejection fraction. Users had less antiplatelet
therapy, more angiotensin II receptor blockers. Despite these differ-
ences, the REACH cardiovascular risk score was similar between
groups (Table 1). Baseline characteristics of all enrolled patients with
data pertaining to calcium antagonist use found similar results
(Supplementary material online, Table S4).
Overall the rate of death was 1.80 per 100 patient years. Event
rates are detailed in Supplementary material online, Table S11.
Multivariable adjusted HRs for the primary and secondary outcomes,
as well as exploratory analyses showed no association between cal-
cium antagonist use at baseline and any outcome (Take home figure,
Table 2).
There was no association between calcium antagonist use and
mortality, regardless of the history of PCI or presence of angina
(Supplementary material online, Tables S12 and S13). In patients with
MI in the year preceding enrolment, there was no association be-
tween calcium antagonist use and mortality (Take home figure,
Table 4).
Sensitivity analyses considering the last assessment of calcium an-
tagonist use prior to an event gave consistent results (Supplementary
material online, Table S8).
When considering LV ejection fraction as a categorical variable
and including a missing category, analyses performed among 31 984
patients showed consistent results. Calcium antagonist use
(n= 8735) compared with non-use (n= 23 249) was not associated
with lower all-cause death [722 (8.3%) and 1800 (7.7%), respectively
with HR 0.97, 95% CI 0.89–1.06; P= 0.56] or lower cardiovascular
death [456 (5.2%) and 1147 (4.9%), respectively with HR 0.98, 95%
CI 0.87–1.09; P= 0.67] (Supplementary material online, Table S10).
Discussion
In this large international study of contemporary stable CAD with a
high rate use of evidence-based secondary prevention therapies,
b-blocker use at baseline was associated with lower 5-year all-cause
mortality only in patients enrolled in the year following MI.
Results were consistent when considering change of b-blocker use
before an event and doses of b-blockers. The use of calcium antago-
nists was not associated with any differences in outcome. b-blocker
use appeared associated with lower cardiovascular mortality in
patients with no history of PCI.
No RCT has shown a benefit of b-blockers compared with pla-
cebo on hard clinical outcomes in stable CAD without LV systolic
dysfunction. Evidence of these agents improving outcome is derived
from old trials in acute MI, mostly performed before the advent of
secondary prevention and reperfusion therapies; the benefit of
b-blockers was mainly driven by their use in the acute phase of MI.10
Observational studies and post hoc RCT analyses have questioned
the benefit from b-blockers on mortality, notwithstanding limitations
in these studies relating to sample size, geographical scope, or
selected patient profile. FAST-MI12 found no association between b-
blocker cessation 1 year after MI and all-cause mortality. A French re-
imbursement database study14 showed no impact on mortality
of stopping b-blockers beyond 1 year after MI without heart failure.
The Kaiser Permanente study13 showed evidence of lower risk of
death with b-blocker use in patients enrolled in the acute phase after
MI. The REACH11 registry found no association between b-blocker
use and mortality in stable CAD outpatients but suggested benefit in
patients with recent prior MI (<1 year); however, LV function and
b-blocker type or dose were unknown. The present results are con-
sistent with a post hoc analysis of the CHARISMA trial15 showing no
association between b-blocker use and lower mortality in a selected
trial population of stable patients with or without prior MI. However,
outcomes may differ between the selected patient populations
enrolled in clinical trials and patients enrolled using similar criteria in
population based observational studies.28,29
In the assessment of calcium antagonists in stable CAD
(Supplementary material online, Table S14), the ACTION16 trial failed
to demonstrate improved mortality compared with placebo. TIBET18
and APSIS19 trials did not show any improvement in mortality when
compared with b-blockers. Other RCTs performed in hypertensive
CAD patients failed to demonstrate an improvement in mortality
with calcium antagonists compared with placebo17 or compared with
b-blocker.20 A meta-analysis21 did not find lower mortality. There
are no robust observational studies from which we can draw
conclusions.
While RCTs are the gold standard to test the efficacy of medical
therapies,30 observational studies may be useful when evaluating the
impact of long-term use of drugs in broad patient populations.28
There are several strengths to the current analyses. CLARIFY was
a large international study encompassing various profiles within stable
CAD (e.g. with or without prior MI or prior revascularization and
with or without angina or ischaemia) and capturing LV function, uses
of treatments over time, doses of b-blockers, and also detailed infor-
mation regarding contraindications or intolerance to b-blockers.
Multivariable adjustment used the REACH risk score as it correlates
well with outcomes.26 Finally, the most robust outcome, all-cause
mortality, was the main outcome of the present analysis, and the
results were consistent when accounting for b-blocker or calcium an-
tagonist status over time, dose, after categorization by presence of
angina or history of PCI or when including patients with missing LV
ejection fraction in the adjustment model.
These findings about b-blockers as well as those from previous
studies are contrary to the preconceived notion that they are benefi-
cial for all CAD patients. b-blockers demonstrated their benefit in
term of clinical outcomes in settings where there was sympathetic
neuro-hormonal activation (LV systolic dysfunction, congestive heart
failure, and acute MI). The absence of benefit in stable CAD without
LV dysfunction or stabilized CAD remote from MI may be explained
by the lack of sympathetic activation. Regarding calcium antagonists
and mortality in a contemporary cohort, our findings are consistent
with the results from available RCTs.16
Limitations
There are several limitations to this analysis. Analyses were not for-
mally prespecified before data collection and the methods of analysis
were not prospectively defined. Patients with severe heart failure or
life-threatening arrhythmias as a complication to recent MI and in
whom the benefit of b-blockers is clear were excluded. Outcomes
were not adjudicated. However, the results were consistent for non-
adjudicated outcomes and for all-cause mortality. Observational
1406 E. Sorbets et al.
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studies have inherent limitations: residual confounding from meas-
ured or unmeasured variables cannot be excluded (related to both
contraindication and indication bias) and could contribute to the
observed differences in mortality between groups. In addition, enrol-
ment and follow-up did not start at the time of treatment initiation or
at the time of diagnosis, which can cause bias. A third of patients with-
out b-blocker at baseline were nor treated because of prior symp-
toms of intolerance or contraindication, which may reflect imbalance
in baseline risk between groups related in particular to comorbidities
such as asthma or COPD. It is noteworthy, however, that the
REACH score at baseline was nearly identical between b-blocker
users and non-users.
Conclusions
In this large contemporary cohort of stable CAD after multivariable
adjustment including LV ejection fraction, b-blockers were not asso-
ciated with lower all-cause mortality or improved outcomes, except
in patients enrolled in the year following an MI. The use of calcium
antagonists was not associated with superior outcomes, regardless of
a prior history of MI.
Considering previous studies and this present analysis, b-blockers
should be preferentially used in the first year following MI. Beyond
1 year following MI or in stable CAD patients without prior MI, both
b-blockers and calcium antagonists may be used for symptom relief
but a mortality benefit should not be assumed. A large adequately
powered RCT would be required to settle the issue of whether first
line anti-ischaemic agents impact prognosis and outcomes in patients
with stable CAD. However, it is uncertain whether it would be feas-
ible to mobilize the resources and patient numbers to adequately ad-
dress this question.
Supplementary material
Supplementary material is available at European Heart Journal online.
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